openFDA
Cure8 regulatory brief
Methylprednisolone Acetate FDA label update (2026-11-04)
Medications
Corticosteroids
Steroids
Regulatory Update
Clinicians
Adult patients
Inflammatory bowel disease
Ulcerative colitis
Why This Matters
This is an FDA label (DailyMed) update for methylprednisolone acetate, an injectable corticosteroid.
The label explicitly lists regional enteritis (Crohn’s disease) and ulcerative colitis among its gastrointestinal indications, so patients and clinicians should know this formulation is recognized for short-term use in IBD flare management when appropriate.
Who Should Pay Attention
Clinicians who treat IBD, adult patients with Crohn’s disease or ulcerative colitis, and caregivers involved in acute flare management.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This DailyMed entry is an FDA drug label update for methylprednisolone acetate (an injectable corticosteroid).
The label lists approved indications, including use “to tide the patient over a critical period” in regional enteritis (Crohn’s disease) and ulcerative colitis, and describes dosing, routes (intramuscular, intra-articular, intra-lesional), and precautions.
If you or your clinician are considering injectable methylprednisolone acetate for IBD, this label clarifies that systemic intramuscular use is an established indication for short-term control of regional enteritis and ulcerative colitis when needed, and provides dosing principles and safety notes (for example, contains benzyl alcohol warning for pediatrics and not to mix with other solutions).
This entry is a regulatory drug-label record rather than a clinical trial or patient guide. For treatment decisions, discuss with your clinician how this formulation and route compare to other steroid options (oral prednisone, budesonide, etc.), the goal of short-term use, and monitoring for steroid-related side effects.
Keep In Mind
This record is a regulatory drug-label document (DailyMed). It describes approved indications, recommended dosing approaches, routes of administration, and safety considerations; it is not a clinical-practice guideline or a clinical-trial report. Treatment choices should be made with a clinician and consider current standards of care and individual patient factors.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorGland Pharma Limited
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedNov 4, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
SOLU-MEDROL FDA label update (2026-07-23)
This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...
Dexamethasone FDA label update (2026-09-04)
Dexamethasone is a systemic corticosteroid with an official label that still includes short‑term use to "tide the patient over a critical period" in Crohn's disease (regional enteritis) and ulcerative colitis.
Solu-Cortef FDA label update (2026-08-27)
This FDA label page documents official prescribing information for SOLU-CORTEF (hydrocortisone), including explicit gastrointestinal/IBD indications (regional enteritis and ulcerative colitis) and IV/IM dosing guidance.